Quotient Sciences Quotient Sciences

X
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
  • A company that focuses on the marketing and distribution of various pharmaceutical products is looking for suppliers of EP Grade Pilocarpine HCl (10 kg -12 kg) API for commercial purposes. The suppliers must support this enquiry with CoA.
    16 Apr 2024
    A company that focuses on the marketing and distribution of various pharmaceutical products is looking for suppliers of EP Grade Monobenzone (600 g) API for commercial purposes. The suppliers must support this enquiry with CoA.
    16 Apr 2024
  • A company that focuses on the marketing and distribution of various pharmaceutical products is looking for suppliers of EP Grade Oxybutynin Hydrochloride (150 g) API for commercial purposes. The suppliers must support this enquiry with CoA.
    16 Apr 2024
    A company that offers various services like formulation development, analytical method development, pre-formulation studies and others is looking for suppliers of Mesalazine API for development purposes. The suppliers must support this enquiry with CoA.
    16 Apr 2024
  • A company that focuses on developing treatment for various ocular diseases and have number of products at various stage of pre-clinical & clinical development is looking for suppliers of Brimonidine (20 g) API for development purposes. The suppliers must support this enquiry with CoA.
    16 Apr 2024
    A company that focuses on developing treatment for various ocular diseases and have number of products at various stage of pre-clinical & clinical development is looking for suppliers of Aceclidine (20 g) API for development purposes. The suppliers must support this enquiry with CoA.
    16 Apr 2024

    Comment Comment

    Reply text-arrow

  • A company that focuses on manufacturing and distribution of various finished formulations used in surgery, dermatology, orthopedics, pediatrics, cardiology, gynecology, therapy and other areas of modern medicine is looking for suppliers of various finished formulation for commercial purposes. The required quantity is 10,000 packs.
    1. Clindamycin 100 mg + Clotrimazole 200 mg suppositories.
    2. Clindamycin 100 mg + Clotrimazole 100 mg + Tinidazole 100 mg suppositories.
    3. Metronidazole 500 mg + Neomycin sulfate 65 000 IU + Nystatin 100 000 IU suppositories.
    4. Neomycin 83 mg + Metronidazole 500 mg + Clotrimazole 100 mg suppositories.
    5. Metamizole 400 mg + Drotaverine hydrochloride 40 mg + Caffeine 60 mg Tablets.
    6. Ibuprofen 400 mg + Drotaverine hydrochloride 80 mg Tablets.
    7. Drotaverine 80 mg + Paracetamol 500 mg Tablets.
    8. Drotaverine 80 mg + Mefenamic acid 250 mg Tablets.
    9. Dicycloverine 10 mg + Mefenamic acid 250 mg Tablets.
    10. Dicycloverine 20 mg + Paracetamol 500 mg + Mefenamic acid 250 mg Tablets.
    11. Orphenadrine citrate 35 mg + Mefenamic acid 250 mg Tablets.
    12. Orphenadrine citrate 50 mg + Aspirin 770 mg + Caffeine 60 mg Tablets.
    13. Hyoscine butylbromide 10 mg + Ketoprofen 100 mg Tablets.
    14. Hyoscine butylbromide 20 mg + Ibuprofen 400 mg + Caffeine 50 mg Tablets.
    15. Hyoscine butylbromide 20 mg + Ibuprofen 400 mg Tablets.
    16. Hyoscine butylbromide 10 mg + Metamizole 250 mg Tablets.
    17. Hyoscine butylbromide 10 mg + Paracetamol 500 mg Tablets.
    16 Apr 2024
    A global pharmaceutical company that focuses in research, development and manufacturing of generic pharmaceuticals and biosimilars is looking for suppliers of various finished formulations for commercial purposes. The supplier must support this enquiry with dossiers.
    1. Oxycodone HCl (5 mg) Capsules. The required quantity is 60,000 units/ year.
    2. Oxycodone HCl (10 mg) Capsules. The required quantity is 60,000 units/ year.
    3. Oxycodone HCl (20 mg) Capsules. The required quantity is 60,000 units/ year.
    4. Oxycodone HCl (40 mg) Capsules. The required quantity is 60,000 units/ year.
    5. Oxycodone HCl (80 mg) Capsules. The required quantity is 60,000 units/ year.
    08 Apr 2024
  • A company with 3 divisions which focuses on manufacturing and development of various finished formulations is looking for suppliers of Various RLDs for development purposes.
    1. Rivaroxaban (2.5 mg/ 10 mg/ 15 mg) Tablets
    2. Rosuvastatin Calcium (5 mg/ 10 mg/ 20 mg/ 40 mg) Tablets
    3. Nortriptyline (10 mg/ 25 mg/ 50 mg/ 75 mg) Capsules
    4. Febuxostat (40 mg/ 80 mg) Tablets
    5. Betahistine (8 mg/ 16 mg) Tablets
    6. Dapagliflozin (5 mg/10 mg) Tablets
    7. Empagliflozin (10 mg/ 25 mg) Tablets
    8. Vonoprazan Fumarate (10 mg/ 20 mg) Tablets
    04 Apr 2024
    A large pharmaceutical manufacturing company that deals in prescription drugs, generic drugs, oncology, non-prescription drugs, veterinary medicines, CNS, anti-infective and hormonal drugs is looking for suppliers of various finished formulations for commercial purposes.
    1. Micronized Progesterone (100 mg X 30) Capsules. The required quantity is 84,797 units.
    2. Micronized Progesterone (200 mg X 30) Capsules. The required quantity is 144,315 units.
    3. Micronized Progesterone (400 mg X 20) Capsules. The required quantity is 1,080 units.
    02 Apr 2024
  • A company that focuses on development of innovative prescription products for aesthetic medicine and medical dermatology is looking for CMO to manufacture Liniment for the treatment of Crow’s feet and hyperhidrosis. The required packaging is 1 ml in dropper. The project launch time is in 2026. The required quantity is 10 batches of 100 kg. The country of distribution is United States. The geographical preference for service provider is United States.
    22 Feb 2024
    A company based in United States that focuses providing solutions in areas specifically defense, intelligence, health & bioscience, transport, energy and critical infrastructure is looking for GMP certified CDMO for intravenous injectables. The country of distribution is United States.
    09 Feb 2024
  • A CMO that focuses on manufacturing, licensing & marketing of various OTC & Rx finished formulations is looking for a GMP certified CDMO for Tech Transfer of Solid, Liquid and Semi-Solid finished formulations. The projected annual manufacturing volume is 30 MT – 1000 MT. The country of distribution is Europe & United Kingdom and the geographical preference for service provider is Europe.
    20 Jan 2024
    A company based in India which focuses on providing multiple services under one roof ranging from custom synthesis to trading of novel chemicals, intermediates, nutraceuticals and excipients is looking for CDMO for Spray Drying for Granules. The required packaging is in 50 kg Carboy. The projected annual manufacturing volume is 1500 kg. The country of distribution is the Saudi Arabia and the geographical preference for service provider is India.
    05 Jan 2024
  • A company that focuses on research, development & manufacturing of injectables is looking for suppliers of Injectable Grade PEG 300 Excipient for commercial purposes. The supplier must support this enquiry with CoA.
    16 Apr 2024
    A company that specializes in the development and manufacturing of APIs and finished dosage pharmaceutical formulations is looking for suppliers of USP Grade Acetylated Monoglyceride (1 kg) Excipient for development purpose. The supplier must support this enquiry with CoA.
    11 Apr 2024
  • A company that focuses on manufacturing and marketing of various injectable and ophthalmic finished formulations is looking for suppliers of Sodium Deoxycholate (20 kg) Excipient for commercial purposes. The supplier must support this enquiry with CoA.
    09 Apr 2024
    A company specializing in the in-licensing development of generic pharmaceuticals and the outsourcing of full-scale commercial batch production looking for suppliers for Ethyl Oleate (450 kg) Excipient for commercial purposes. The supplier must support this enquiry with CoA.
    01 Apr 2024

Interviews #SpeakPharma

  • “We’ve partnered over 900 drugmakers by bringing together three businesses”
    This week, SpeakPharma interviews the CEO of Axplora, Sylke Hassel, along with Stephan Haitz, president of its business unit Novasep CDMO. Axplora is a leading and reliable API manufacturing partner to some of the world’s biggest pharma and biotech companies. Hassel and Haitz discuss how the pandemic has transformed the CDMO landscape, the idea behind setting up a scientific advisory board, and the exponential growth being seen in the antibody-drug conjugates space. Excerpts: Can you briefly take us through Axplora’s history and vision? Hassel: Axplora Group was founded in April 2022 by merging global API manufacturers PharmaZell and Farmabios, as well as leading CDMO — Novasep. The vision was to become a reliable partner to the world’s leading pharma and biotech companies. The group continues to promote the three well-known historical brands while repositioning them in their respective markets — Farmabios is for steroids and highly potent products, Novasep CDMO for small molecule APIs and antibody-drug conjugates (ADCs), and PharmaZell for specialty products and generics. By bringing together these three businesses, we are able to serve more customers with a broader technology portfolio over the entire lifecycle of their products. The partnership starts early in their R&D phases, goes through the commercial lifecycle, and even continues when the product becomes a generic. By joining forces, we make a drastic difference in terms of scale, visibility, market presence, and security of supply. We have partnered over 900 leading pharma companies over the last three years to deliver sustainable, technology-advanced API products and services that benefit millions of patients across the world. 🔑 HIGHLIGHTS// founded in 2022: PharmaZell (steroids and high potent) + Farmabios (generics) + CDMO Novasep (small molecules and antibody-drug conjugates) Axplora has recently set up a scientific advisory board (SAB). How will the formation of the SAB further innovation? Hassel: To us, innovation is the engine for future growth. And the launch of our SAB in November 2023 is a step towards furthering innovation. The SAB brings together five industry experts in key areas of API development and manufacturing – flow chemistry, catalysis, electrochemistry, steroids, biotechnology, and ADCs. Our five international experts — Dr. David Cantillo of the University of Queensland, Prof. Alois Fürstner of the Institute für Kohlenforschung, Prof. Kerry Chester from the University of London, Prof. John Woodley from the Technical University of Denmark, and Dr. Michael Reschke from the Technical University of Hanover — aim to support our R&D team of over 140 to meet next-generation challenges. 🔑 HIGHLIGHTS// Scientific Advisory Board (SAB) = Flow Chemistry, Catalysis, Electrochemistry, Steroids, Biotechnology, and antibody-drug conjugates/ Innovation focus How has the business of API process development and manufacturing changed in recent years? What are the main challenges you face? Hassel: The Covid-19 pandemic has transformed the CDMO landscape. The industry reacted in record time. For example, in a matter of months, Novasep CDMO’s Mourenx site was ready to produce the active pharmaceutical ingredient (API) for a Covid anti-viral therapy, thereby preventing hospitalizations and deaths in high-risk patients. After Covid-19, the industry went through a reset, especially as biotech funding reduced. Therefore, CDMO companies had to reinvent themselves and focus on specialized areas such as ADCs, a molecule that Axplora has produced for over 15 years in Le Mans. The CDMO industry is still undergoing significant transformation. The growth of novel therapies, global supply chain uncertainties, and increasingly tough competition are all examples that require us to continuously adapt to market trends. Understanding these transformations is essential to stay at the forefront of the curve and harness our innovation potential. As mentioned previously, our SAB plays a key role in identifying market trends and in providing insight and guidance to our R&D organization to develop and provide innovative offerings. 🔑 HIGHLIGHTS// novel therapies, global supply chain uncertainties, increasingly tough competition/ identifying market trends and providing insight to R&D Can you tell us a bit more about the CDMO business and your vision? Haitz: We manufacture APIs for our pharmaceutical clients to help them create new drugs that ultimately benefit millions of patients. Currently, we supply over 70 drugs to the market. Our objective is to be a reliable partner for our customers once the drug is commercialized, and ensure security of supply to help patients’ lives. Our challenge as a CDMO is to build a pipeline and then to manufacture the products on time with the necessary quality for our customers, so we need our commercial and operations teams working in synergy. We also have robust processes to ensure that we are cost-competitive. However, we constantly need to add new projects to renew our business and to compensate for the product lifecycle decline. Long relationships with customers are key to our success. We are a manufacturing company with developments and technologies that make a difference. We develop robust, efficient, and scalable processes to ensure we can supply the industrial quantities needed for the market. Our customers are highly appreciative of our technical capabilities – we are a leading company in ADCs, Novasep CDMO is a pioneer in chromatography and chiral separation, and we are well-known for handling hazardous chemistry, which we mainly operate in Leverkusen (Germany) and Chasse-sur-Rhône (France). At the end of the day, we use these technologies to provide the best possible customer service. We are fundamentally a service provider. 🔑 HIGHLIGHTS// 70 drugs/ customization/ commercial and operation synergy/ cost competitiveness/ service provider The market for ADCs is increasing at a fast pace. Tell us about your development and manufacturing services for ADCs. Haitz: These innovative, targeted anti-cancer treatments are benefiting thousands of patients around the world. Currently, there has been an exponential growth in the number of ADCs in development. Among our strong network of 10 manufacturing sites, we have a state-of-the-art facility in Le Mans (France) that has over 15 years of experience in the synthesis and purification of ADCs. We are involved in six out of the 14 approved commercial ADC molecules on the market in Le Mans. We also demonstrate agility in responding to evolving product demand for clinical trials, and also help accelerate market launches. We offer both payload and linker production as well as bio-conjugation services. Quality is key for our customers and our services help them deliver cutting-edge drugs for cancer care. Last month, we announced an investment of €8 million (US$ 8.59 million) in our Le Mans site to further expand our capacity for ADC manufacturing. We are a leader in ADC business, and continue to expand it. Our objective is to help our customers bring breakthrough treatments to the market as soon as possible, thereby helping patients worldwide. 🔑 HIGHLIGHTS// anti-cancer treatments/ 10 manufacturing sites/ accelerate market launches/ payload and linker production as well as bioconjugation services/ investment of €8 million in ADCs site

    Impressions: 395

    https://www.pharmacompass.com/speak-pharma/we-ve-partnered-over-900-drugmakers-by-bringing-together-three-businesses

    08 Apr 2024

Data Compilation & Company Tracker #PharmaFlow

  • FDA approves four oligonucleotide therapies in 2023; Novartis, GSK, Novo bet big
    In the intricate world of molecular biology, oligonucleotides stand out as versatile, powerful molecules. Oligonucleotides are essentially short, single strands of DNA or RNA that modulate gene expression. There are various oligonucleotide therapy (ONT) agents (such as antisense, deoxyribozymes, siRNA and CRISPR/Cas) that offer promising therapeutic tools.A variation of gene therapy, oligonucleotide gene therapies (OGTs) are manufactured using synthetic oligonucleotides. These therapies are designed to enter cells. ONTs act like tools that can fine-tune the behavior of certain genetic instructions, and are therefore often designed to treat rare and genetic diseases and cancers. Sometimes, they may be delivered into cells through lipid nanoparticles or adeno-associated viruses (AAV), halting the translation of a specific protein. Oligonucleotides have also revolutionized vaccine development through the creation of nucleic acid vaccines, such as mRNA vaccines.The first oligonucleotide drug, known as fomivirsen, was approved by the US Food and Drug Administration (FDA) back in 1998. It was developed by Ionis Pharmaceuticals (then known as Isis Pharmaceuticals), and was approved to treat a rare eye disease. However, ONT approvals have picked up since 2016. Currently, there are 20 oligonucleotide drugs approved by the FDA and the European Medicines Agency (EMA) and a majority of them treat orphan and rare diseases.In 2023, FDA approved four ONTs — AstraZeneca-Ionis’ Wainua (eplontersen), Novo Nordisk owned Dicerna Pharmaceuticals’ Rivfloza (nedosiran), Biogen-Ionis’ Qalsody (tofersen) and Iveric Bio’s Izervay (avacincaptad pegol).In 2021, the global ONT market size was estimated to be US$ 18.2 billion. It is expected to increase to US$ 51.4 billion by 2029, growing at a compounded annual rate (CAGR) of 13.85 percent. Similarly, the market for oligonucleotides synthesis (or the process of producing oligonucleotides) was estimated at US$ 7.7 billion globally in 2022 and is expected to grow 11.8 percent CAGR to reach US$ 16.4 billion by 2030. Some of the bigger players in oligonucleotides synthesis are Danaher Corporation, Thermo Fisher Scientific, Merck KGaA, Eurofins, Agilent, Bio-Synthesis, EUROAPI, Eurogentec, STA Pharma, and Bachem.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available)ONTs address neuro disorders; four ONTs bring in US$ 1.24 bn for AlnylamONTs are widely applied to treat neurodegenerative diseases, such as Duchenne muscular dystrophy (DMD). Multiple ONTs have been approved in Europe and the US for DMD, such as Exondys 51 (eteplirsen), Vyondys 53 (golodirsen), and Amondys 45 (casimersen) from Sarepta and NS Pharma’s Viltepso (viltolarsen). Last year, Ionis bagged two approvals in the space. FDA approved its Biogen-partnered therapy Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS). The agency also approved AstraZeneca and Ionis’ drug Wainua (eplontersen), rendering it as the first self-administered treatment for a rare nerve damage disease, known as hereditary transthyretin amyloidosis (ATTR-PN). Analysts estimate global peak sales for Wainua to come in at US$ 750 million for ATTR-PN alone. The drug is also being tested for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a rare heart muscle disorder.Alnylam Pharmaceuticals has also successfully brought four ONTs to market in recent years — Onpattro (patisiran) and Amvuttra (vutrisiran) for rare nerve diseases, and Givlaari (givosiran) and Oxlumo (lumasiran). Givlaari has been approved to treat acute hepatic porphyria (a liver enzyme deficiency) while Oxlumo treats primary hyperoxaluria (a disorder characterized by increased urinary oxalate excretion). The four ONTs brought in US$ 1.24 billion for Alnylam in 2023.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Novartis buys rights to siRNA therapy, GSK bets big on ONT pipeline through dealsAfter Alnylam discovered inclisiran (Leqvio), Novartis acquired global rights to the therapy in a US$ 9.7 billion deal. Leqvio was the first FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction. It brought in US$ 355 million for Novartis in 2023.GSK has increasingly been investing in its ONT pipeline. The British pharma has promised over US$ 5 billion in upfront and milestone payments in multiple deals. In February, GSK exercised its option to license Elsie Biotechnologies’ discovery platform to find and develop novel ONTs. GSK has also entered a discovery collaboration with Wave Life Sciences.Last July, Japanese drugmaker Astellas Pharma completed its approximately US$ 5.9 billion buyout of New Jersey-headquartered Iveric Bio. Iveric focuses on retinal diseases and the deal gives Astellas drug candidates to treat about 160 million people with eye ailments. Subsequently, in August, Iveric’s Izervay (avacincaptad pegol) was approved by the FDA as a new treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).After Novo Nordisk acquired RNAi technology company Dicerna Pharmaceuticals for US$ 3.3 billion in 2021, the latter’s once-monthly RNAi therapy Rivfloza (nedosiran) saw FDA approval last October. Rivfloza was okayed for children nine years and older to treat a rare genetic condition that affects the kidneys, known as primary hyperoxaluria type 1 (PH1).View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Ionis tees up NDAs for rare disease treatments after two late-stage trial winsThe industry is looking for cures to a wide spectrum of diseases like cancer (such as melanoma, pancreatic, liver, glioblastoma, breast and ovarian cancer), cystic fibrosis, Alzheimer’s disease, Parkinson’s disease, hepatitis B, asthma, Rett syndrome, non-alcoholic steatohepatitis, and IgA nephropathy through its research on ONTs.In January, Ionis announced late-stage results wherein its RNA-targeted hereditary angioedema (HAE) candidate, donidalorsen, significantly reduced the rate of HAE attacks in patients treated every four weeks and patients treated every eight weeks. The California-based biotech is readying a new drug application (NDA) to submit to the FDA. HAE is a rare and life-threatening genetic disease that causes unpredictable and frequent severe swelling of the skin, gastrointestinal (GI) tract, upper respiratory system, face and throat. This year, Ionis’ olezarsen was granted fast track designation by the FDA for the rare genetic disease familial chylomicronemia syndrome (FCS). Last September, olezarsen had met its primary endpoint of reducing abnormally high levels of triglycerides in a late-stage trial in patients with the metabolic disorder. Currently, there are no FDA-approved treatments for this condition. If okayed, olezarsen is likely to bring in US $849 million in sales for Ionis by 2032.In March, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to two in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent (TD) anemia in certain adult patients with myelodysplastic syndromes. The agency assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024, for Geron’s NDA for imetelstat. It is among the most anticipated drug launches this year.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Our viewDeveloping ONTs is a field fraught with challenges, such as toxicity and drug delivery. There are safety concerns as well as concerns around delivering the therapy. However, technological breakthroughs and collaborations between pharma firms and contract research organizations that focus on drug delivery are continuously working towards addressing these challenges. All in all, we foresee exciting times ahead for ONTs.  

    Impressions: 1694

    https://www.pharmacompass.com/radio-compass-blog/fda-approves-four-oligonucleotide-therapies-in-2023-novartis-gsk-novo-bet-big

    #PharmaFlow by PharmaCompass
    21 Mar 2024

Monthly Stock Recap #PipelineProspector

  • Pipeline Prospector March 2024: FDA approves pathbreaking NASH drug from Madrigal, two meds for PAH
    March was clearly a month of drug approvals, as the US Food and Drug Administration (FDA) went on an overdrive, green-lighting several therapies before the close of the first quarter (Q1 2024). Amongst them was the first drug to treat non-alcoholic steatohepatitis (NASH) and a breakthrough therapy that treats pulmonary arterial hypertension (PAH).However, the buoyancy in drug approvals didn’t play out in the stock markets and most pharma indices witnessed a marginal dip. The Nasdaq Biotechnology index (NBI) fell marginally (-0.43 percent) to 4,429.97 from 4,449. The SPDR S&P Biotech ETF index (XBI) dropped 4.6 percent to 94.89 after ending February at 99.44. And the S&P Biotechnology Select Industry index (SPSIBI) was down by 3.4 percent from 7,662.14 to 7,402.47 in March.In deals, AstraZeneca bought two companies, shoring up its cancer and rare disease pipelines. The Anglo-Swedish drugmaker first bought France’s Amolyt, which focuses on rare endocrine diseases, for a total of US$ 1.05 billion and then acquired next-generation cancer drugmaker Fusion Pharmaceuticals for around US$ 2 billion. AstraZeneca’s stock was up 4.6 percent in March. Novo Nordisk (stock up 4.8 percent) agreed to acquire Cardior Pharmaceuticals for up to US$ 1.1 billion in order to boost its pipeline for cardiovascular diseases.Access the Pipeline Prospector Dashboard for March 2024 Newsmakers (Free Excel)FDA okays first drug for NASH; Wegovy approved as med to reduce heart risksFor quite some time, the drug development field for the liver condition non-alcoholic steatohepatitis (NASH) has been a graveyard for failed programs. In March, the field celebrated a hurrah moment when Madrigal Pharmaceuticals (stock up 6 percent) won the race to have the first NASH treatment approved by the FDA. Madrigal’s oral drug Rezdiffra (resmetirom) treats adults with NASH, a disease that causes histologic liver damage and occurs in patients who are not alcoholics and are often obese or have type 2 diabetes. The approval has opened a multi-billion dollar opportunity for Madrigal.The GLP-1 agonist drugs that are used to treat diabetes and obesity have shown heart-related benefits too in clinical trials. Last month, FDA approved Novo Nordisk’s Wegovy (semaglutide) to reduce the risk of cardiovascular death, heart attack, and stroke in obese or overweight adults with cardiovascular disease (CVD). The move makes Wegovy the first weight-loss medication that is also approved to help prevent life-threatening cardiovascular events. The approval was hailed as a major advancement in public health.Another significant FDA approval was granted to Akebia’s anemia drug, vadadustat. After being turned down in March 2022, Akebia has now been approved to treat anemia caused by chronic kidney disease (CKD) in dialysis patients.Access the Pipeline Prospector Dashboard for March 2024 Newsmakers (Free Excel) FDA okays two meds for PAH; Italfarmaco’s Duvyzat approved for DMDFDA approved a breakthrough therapy from Merck, known as Winrevair (sotatercept-csrk), to treat adults with hypertension that is caused by constriction of the arteries in the lungs, known as pulmonary arterial hypertension (PAH). The agency also approved Johnson & Johnson’s Opsynvi – a single-tablet combination of macitentan and tadalafil – for the chronic treatment of adults with PAH. With this approval, Opsynvi became the only once-daily combination therapy for PAH.Apart from PAH, there was another significant approval for hypertension. FDA okayed Idorsia’s once-daily treatment Tryvio (aprocitentan) in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not able to adequately control their BP on other drugs. Idorsia’s stock was up 50 percent in March. Tryvio is the first oral anti-hypertensive therapy, which works via a new therapeutic pathway, to be approved in almost 40 years.The US agency also approved Italfarmaco Group’s oral medication Duvyzat (givinostat) for the treatment of Duchenne muscular dystrophy (DMD) in patients six years of age and older. Duvyzat is the first nonsteroidal drug approved to treat patients with all variants of DMD, a genetic disorder characterized by progressive muscle degeneration.Orchard Therapeutics’ Lenmeldy was also greenlit by the FDA as the first gene therapy in the US for a debilitating and rare pediatric disorder, known as metachromatic leukodystrophy (MLD).Access the Pipeline Prospector Dashboard for March 2024 Newsmakers (Free Excel) Breyanzi okayed for complex leukemia; Tevimbra approved for esophageal cancerAmong cancer treatments, FDA granted an accelerated approval to BMS’ Breyanzi, making it the first and only CAR-T cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). BMS’ stock was up 6 percent in March.BeiGene’s PD-1 blocker Tevimbra (tislelizumab) finally got the go ahead from the FDA as a treatment for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.FDA also granted accelerated approval to Takeda’s Iclusig (ponatinib) to be used with chemotherapy for newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), a type of blood cancer of the bone marrow and blood.Access the Pipeline Prospector Dashboard for March 2024 Newsmakers (Free Excel) Pfizer-Takeda’s Adcetris posts trial win in DLBCL; FDA defers donanemab approvalIn clinical trials, there was some positive news from a phase 3 trial on Pfizer and Takeda’s drug Adcetris, which is known as a standard of care in classical Hodgkin lymphoma. The med has now shown to be efficacious in diffuse large B-cell lymphoma (DLBCL), a common type of non-Hodgkin lymphoma, when used in combination with two other drugs — lenalidomide and rituximab.In a late-stage trial, Novo Nordisk’s broadly used blockbuster diabetes drug Ozempic (semaglutide) slashed the risk of kidney disease progression and death from cardiovascular or kidney complications by 24 percent in diabetic patients with CKD. In negative news from the trials, the much anticipated approval of Eli Lilly’s donanemab scheduled for March was deferred as FDA opted to convene a panel of independent experts to assess the drug’s safety and efficacy. Similarly, Amylyx’s Relyvrio (sodium phenylbutyrate and taurursodiol), a promising investigational treatment for amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, failed to demonstrate it works better than a placebo in a 48-week long trial. ALS is a fatal motor neuron disease characterized by progressive degeneration of nerve cells.Access the Pipeline Prospector Dashboard for March 2024 Newsmakers (Free Excel) Our viewWith so many drug approvals, March was a good month for the biopharma industry. While it may look like the markets didn’t cheer the approvals, all the three indices — the NBI, XBI, and SPSIBI — ended the quarter in the green, growing 2.1 percent, 7.3 percent, and 6.4 percent, respectively, between January 2 and March 28. As we enter the second quarter of 2024, we hope the buoyancy in drug approvals and the indices is maintained.Access the Pipeline Prospector Dashboard for March 2024 Newsmakers (Free Excel) 

    Impressions: 665

    https://www.pharmacompass.com/pipeline-prospector-blog/march-sees-approvals-of-pathbreaking-nash-drug-from-madrigal-two-meds-for-pah

    PharmaCompass.com
    04 Apr 2024

Weekly News Recap #Phispers

  • Vertex buys Alpine Immune Sciences for US$ 4.9 billion; Merck KGaA signs ADC deal with AI biotech Caris
    This week’s Phispers comes packed with deals, approvals and trial wins. Vertex Pharmaceuticals has decided to bet big on immunotherapies by buying Alpine Immune Sciences for around US$ 4.9 billion in cash. Merck KGaA has entered into a multi-year partnership with Caris Life Sciences, a next-generation AI TechBio company and precision medicine pioneer, to develop novel antibody drug conjugates (ADCs). In devices business, Johnson & Johnson MedTech has picked up Shockwave Medical for around US$ 13.1 billion.In approvals, the US Food and Drug Administration (FDA) has allowed Johnson & Johnson-Legend’s Carvykti, and Bristol-Myers Squibb-2seventy bio’s Abecma as earlier lines of treatment for blood cancer. FDA has granted AstraZeneca and Daiichi’s oncology med Enhertu a broad (accelerated) approval to treat various cancers that are stimulated by a certain protein.In trials, BMS’ schizophrenia drug KarXT and AstraZeneca’s Imfinzi saw late-stage wins.In regulatory news, India’s Kilitch Healthcare was hit with a scathing warning letter from FDA over alarming conditions at its facility in Mumbai. And Jubilant Generics was issued a Form 483 by the agency.Vertex bolsters its pipeline for autoimmune diseases with US$ 4.9 bn Alpine buyVertex Pharmaceuticals is acquiring Alpine Immune Sciences for US$ 4.9 billion. The deal gives Vertex access to Alpine’s protein-based immunotherapies for autoimmune diseases. Through the acquisition, Vertex gains a promising drug known as povetacicept, which is in mid-stage development to treat IgA nephropathy (IgAN), a serious kidney disease.Merck KGaA inks ADC deal with Caris: Merck KGaA has entered into a multi-year partnership with Texas-based Caris Life Sciences for the discovery and development of first-in-class ADCs for cancer patients. The German drugmaker will provide Caris’ therapeutic research arm an undisclosed upfront payment. Caris will also be eligible to receive milestone payments of up to US$ 1.4 billion along with tiered royalties. Meanwhile the US’ Merck (MSD outside US) also snapped up a biotech startup — Abceutics — that was spun out of the laboratory of the University at Buffalo for about US$ 208 million. Abceutics’ payload-binding selectivity enhancer (PBSE) technology is meant to boost the safety of ADCs.J&J buys Shockwave Medical for US$ 13.1 bn: J&J has agreed to buy Shockwave Medical for about US$ 13.1 billion. The move boosts its cardiac-health-centric medical devices business. Shockwave Medical makes devices that rely on shockwaves to break down calcified plaque within heart vessels, mirroring the methodology used in treating kidney stones.FDA approves Carvykti, Abecma as earlier lines of blood cancer treatmentJ&J and Legend’s Carvykti has become the first and only BCMA-targeted therapy approved by FDA for patients with relapsed or refractory multiple myeloma, who have received just one prior line of treatment. In 2022, the CAR-T therapy was approved by the US agency as a fifth-line option for multiple myeloma patients and now it has become a second-line option. The approval is an important milestone in J&J’s plans to make Carvykti (ciltacabtagene autoleucel) a US$ 5 billion-plus asset at peak yearly sales. It brought in US$ 500 million last year and following the label expansion, analysts predict US$ 950 million in sales this year and as much as US$ 7.6 billion in global peak sales.FDA also greenlit BMS and 2seventy bio’s Abecma (idecabtagene vicleucel) for triple-class exposed relapsed or refractory multiple myeloma after two prior lines of therapy. Both therapies significantly reduced the risk of disease progression or death in their respective phase 3 trials – Carvykti by 59 percent and Abecma by 51 percent.Astra-Daiichi’s Enhertu wins broad approval: AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been granted accelerated approval in the US to treat adult patients with HER2-positive solid tumors that have spread or cannot be surgically removed. These patients have undergone prior treatment and have no satisfactory alternative options available. Now, with this broad approval, Enhertu has become the first ADC okayed to treat such tumors anywhere in the body.BMS’ schizophrenia drug reduces symptoms without weight gain in phase 3 trialLate-stage interim results have shown that BMS’ schizophrenia drug KarXT (xanomeline-trospium) continued to improve symptoms of the severe mental disease at 52 weeks. More significantly, this was achieved without weight gain, a common side effect associated with other antipsychotics. In fact, most patients (65 percent) experienced reductions in weight over the course of the trial with a mean weight decrease of 2.6 kilograms observed at one year. KarXT was the lead candidate in the New Jersey drugmaker’s US$ 14 billion buyout of Karuna Therapeutics. FDA has given it a Prescription Drug User Fee Act (PDUFA) date of September 26.Diabetes drug may slow impact of Parkinson’s disease:  Patients with Parkinson’s disease who took Sanofi’s diabetes med lixisenatide did not see worsening of motor symptoms after one-year of clinical trial, a paper published in the New England Journal of Medicine said. This development was hailed as a vital advance in the decades-long quest for a drug to slow the impact of Parkinson’s disease.AstraZeneca’s Imfinzi improves survival in phase 3 lung cancer trial: Imfinzi (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in a phase 3 trial. This makes the blockbuster drug the first and only immunotherapy to demonstrate survival benefit for this aggressive form of lung cancer in a late-stage trial. Imfinzi had clocked sales of US$ 4.24 billion in 2023.FDA issues warning letter to India’s Kilitch; Jubilant hit with Form 483India’s Kilitch Healthcare was hit with a scathing warning letter from the FDA over alarming conditions at its facility in Mumbai. It was found that staff worked barefoot in sterile rooms, operated machinery without goggles, leaned over opened and filled eye drop bottles and failed to disinfect components that touched the facility walls. FDA found the facility in “disrepair” with peeling paint, stains, and residues. In November last year, Kilitch had recalled 27 eye drops in the US market due to safety concerns.Jubilant slammed with Form 483: India’s Jubilant Generics was issued a Form 483 following an FDA inspection of its Bhagwanpur (Uttarakhand, India) facility between January 25 and February 2. During cleaning checks, FDA found evidence that some medicines may not have met quality standards (out-of-specification drugs). Jubilant Generics failed to identify a root cause of why these drugs failed quality standards. The company also could not take appropriate corrective and preventative actions. Furthermore, it distributed the affected lots in the US market.  

    Impressions: 984

    https://www.pharmacompass.com/radio-compass-phisper/vertex-buys-alpine-immune-sciences-for-us-4-9-billion-merck-kgaa-signs-adc-deal-with-ai-biotech-caris

    #Phispers by PharmaCompass
    11 Apr 2024

Content #LearnMore

  • View Sharp`s clinical trial supply & contract pharmaceutical packaging services for injectables and oral dosage forms on PharmaCompass.
    View Sharp`s clinical trial supply & contract pharmaceutical packaging services for injectables and oral dosage forms on PharmaCompass. What is pharmaceutical contract packaging and how is Sharp a reliable packaging partner for the pharmaceutical and biotech industries? Pharmaceutical packaging can be defined as a set of operations including filling, sealing, packaging, and labeling of semi-finished or finished products. Pharma packaging is an economical means to present, preserve, identify, provide information, maintain product integrity, and ensure stability. It also plays a crucial role in the transportation of sensitive and strictly controlled products. Pharmaceutical contract packaging refers to packaging that is executed and supplied by a licensed third-party service provider that comprises both initial packaging and repackaging. These contract packaging service providers may offer clinical and commercial packaging solutions for pharmaceutical products. Pharmaceutical contract packaging organizations are well-equipped to offer a comprehensive range of primary, secondary, and tertiary packaging solutions. Primary packaging surrounds the pharmaceutical formulation and includes bottles, blisterings, pouches, sachets, tubes, auto-injector pens, etc. Whereas secondary packaging offers further external protection and includes artwork design, labeling for parenteral and injectables, child-resistant and compliance prompting packaging, etc. Additionally, tertiary packaging is used during transportation to absorb physical impacts, moisture, and dust and includes cardboard boxes, stretch wraps, shrink films, and wooden and plastic pallets. Sharp is a leading contract packaging organizations that offer pharmaceutical packaging services among others. It has more than 70 years of experience in pharmaceutical clinical packaging, clinical trial supply services, and small-scale sterile manufacturing. Sharp has more than 2,000 employees who work in its state-of-the-art GMP facilities in the US, UK, Belgium, and the Netherlands. Sharp, offers contract manufacturing and packaging services and support from phase I clinical trial supplies to commercial launch and lifecycle management to its pharmaceutical and biotechnology partners across the world. It has deep expertise in clinical trial packaging and labeling along with a skilled global design team that utilizes cutting-edge software and technology ensuring patient-friendly and differentiated packaging for drug products. Apart from this, Sharp is also a reliable partner for sourcing packaging material and offers integrated pharmaceutical packaging and labeling services along with over-encapsulation of oral solids and the production of placebo capsules for study blinding. Sharp is a contract packaging organization that offers commercial packaging services including contract blister packaging services, bottle packaging, sachet packaging, injectable packaging, and other solid dose packaging solutions. Additionally, it offers clinical packaging and labeling solutions such as clinical trial material packaging, clinical trial packaging and labeling, clinical trial logistics and packaging, and clinical trial supply services, or clinical supplies. Its clinical and commercial packaging services are outlined below: Clinical Packaging Solutions Sharps clinical packaging solutions encompass primary packaging and labeling and secondary packaging. Its pharmaceutical primary packaging offers reliable clinical packaging services, clinical supply chain services, primary packaging solutions, and cold-chain secondary packaging and labeling at 2-8°C, -20°C, and even at -70°C. Sharp also provides reliable clinical pharma packaging services and labeling, secondary packaging solutions, pharmaceutical clinical packaging and labeling solutions along with expertise and capabilities in handling cold-chain pharmaceutical labeling and packaging from 2-8°C to -70°C. Commercial Packaging Solutions For more than 65 years, Sharp has been providing a full range of commercial primary and secondary packaging solutions, blister packaging, and contract manufacturing and packaging services for pharmaceutical oral solid dosage forms. It offers contract blister packaging services and bottle packaging for pharmaceutical drug products. Apart from this Sharp provides pharma packaging contract services for small and large-volume batch sizes of injectables. It offers pharmaceutical packaging services for cold chain storage, packaging in temperature- and light-controlled environments, serialization, and customized distribution. Additionally, Sharp is involved in the pharma packaging of oral solids, liquids, and semi-solids. Moreover, Sharp is a premier commercial packaging service provider for high-value, low-volume gene therapy. It also offers pharmaceutical packaging services, expertise, and powerful technology that facilitates product serialization and aggregation. Therefore, Sharp’s pharma packaging contract services, spanning from clinical supplies to commercial include pharma clinical trial material manufacturing, clinical primary packaging services, clinical secondary packaging solutions, clinical trial packaging and labeling, and clinical trial logistics and packaging. Furthermore, Sharp’s contract manufacturing and packaging services encompass commercial pharma packaging solutions and labeling and supply services. Consequently, all the aforementioned offerings position Sharp as a one-stop-shop contract pharmaceutical packaging service provider for clinical and commercial scales. How does Sharp address challenges related to clinical labeling and secondary packaging? Sharp has over 70 years of experience and is a pioneer in clinical trial supply services and pharmaceutical packaging. Dedicated to the right-first-time principle, Sharp is a reliable partner for secondary packaging and clinical pharmaceutical labeling and packaging. It offers a wide range of quick, scalable clinical trial packaging services and labeling and packaging solutions in all formats, with capabilities spanning the complete lifespan of investigational medicinal products (IMPs). Moreover, Sharp can also address challenges related to packaging and labeling and offers pharmaceutical packaging and labeling services and clinical packaging and labeling services to its clients. Additionally, its clinical packaging and labeling solutions also include in-house auxiliary variable data printing outsourced booklet labels; client-supplied randomization fully supported; and annex 13 compliant and 21 CFR Part 11 compliant PRISYM software for label design. Sharp's pharmaceutical packaging and labeling services include single and multi-panel labels and booklets; 2D barcoding capabilities, randomized and open; 128 barcoding. It also offers; regulatory and translation services; sequentially numbered, variable text; code break, and randomized generation among other clinical packaging and labeling solutions. Sharp is a leader in providing pharmaceutical clinical packaging, contract packaging services, and labeling and supply services in compliance with strict regulatory guidelines. It has special pharma packaging and labeling expertise and capabilities for packaging drug products. Sharp addresses various challenges related to pharma packaging and labeling which includes: Sharp can provide cold-chain pharmaceutical labeling and packaging from 2-8°C to -70°C for drug products that need low temperatures for their transportation and storage. Sharp can support the secondary packaging for most complex drug candidates, such as controlled substance packaging (DEA schedule I-V), and has the capabilities to scale up to commercial supplies. Its design and logistics staff can also assist with the challenges of blinding products and syringes for clinical trial services. Sharp does this by providing annex 13 compliant and 21 CFR Part 11 compliant PRISYM software for label design, client-supplied randomization fully supported, and in-house auxiliary variable data printing outsourced booklet labels. With issues related to timely delivery and efficient labeling, Sharp provides pharmaceutical labeling and packaging solutions by using Scan assembly technology and Interactive Response Technologies (IRT), storage, and distribution. To overcome the label readability issues for clients worldwide, Sharp designs and prints multilingual clinical labels. Therefore, Sharp acts as a one-stop-shop packaging organization that provides pharmaceutical contract packaging services, clinical primary packaging services, primary and secondary clinical packaging, and labeling and supply services to its clients worldwide. What range of packaging design and kitting services does Sharp offer? Sharp is a market leader in the design and delivery of primary and secondary packaging. Due to its structural, graphic, and design engineers as well as its understanding of supply chain and regulatory issues, Sharp excels in pharmaceutical packaging. Sharp has years of experience in creating cutting-edge pharma packaging solutions. It is skilled in brand creation, modifying current artwork, marketing research, FDA filing standards, 3D rendering, senior, child-friendly, or child-resistant design, and labeling and supply services. Sharp's global design team provides the creativity and accuracy required to design highly functional and compliant primary and secondary commercial and clinical pharma packaging services. Sharp offers a wide range of design services and pharmaceutical packaging solutions using the latest tools and technologies to guarantee premium and user-friendly product packaging. Additionally, it provides structural and graphic design development for quick launch and regular upgrades for commercial artwork. Sharp’s wide range of packaging design services for pharmaceutical products includes: Artwork Design Services: Sharp can provide pharma packaging contract services including customized artwork as per specific markets from initial mock-ups to product registration. Packaging Samples: Sharp’s contract pharmaceutical packaging services can create production-quality models for use in marketing presentations, human factor research, and photography that closely match the commercial package. Tray Design: Sharp precisely assesses product components to create a tray design that best suits the drug. 3D Printing: Sharp can rapidly confirm that all product components fit by using its technology to create 3D printed prototypes of trays and other packaging component designs. Shipper and Pallet Design: The structural designers at Sharp develop pallet layouts and shippers based on finished items to guarantee drug safety during distribution and storage. CR/SF Compliant Design and Testing: Sharp offers pharmaceutical contract packaging services and can determine the level of toxicity in child-friendly packaging. Various structural design services offered by Sharp include end-user interactions and compliance; child-resistant, senior-friendly (CR/SF) design; tamper evident features; multiple-component kitting requirements; and sustainable or specified materials. Additionally, Sharp’s graphic design capabilities include serialization artwork; brand identity; complete package graphics; product and package illustrations; and late-stage customization. Sharp’s broad range of tailored kitting options for medical devices, pharmaceuticals, and biotechnology calls for the packaging of multiple components into a single, self-contained unit. The design team at Sharp offers commercial packaging solutions and helps clients create a kit that best meets the end-user needs and product specifications. Its kitting services include labeling, tray packing, and boxing with comprehensive verification inspection to ensure the highest level of quality. How does Sharp manage the packaging of sterile formulations to ensure product integrity? Sharp has almost seven decades of packaging experience and it provides pharmaceutical packaging solutions for sterile and non-sterile formulations while maintaining the integrity and quality of products. It offers contract pharmaceutical packaging services and package design services from its US and EU facilities for injectables containing both small and large-volume batch sizes. For product launch and sample programs, its international design team works with clients to provide pharma packaging solutions and determine the optimal vial, prefilled syringe, and autoinjector packaging options. Through its partnership with Berkshire Sterile Manufacturing (BSM), Sharp also offers small-scale isolator-based sterile fill-finish options. It specializes in pharmaceutical clinical packaging and commercial packaging in cold chain storage, packaging in temperature and light-controlled environments, and specialty distribution for injectable drug products.  It also supports multi-country launches from the US and EU. Sharp has experience in parenteral and injectable format labeling and packaging such as vials, autoinjectors, syringes, and pens. Its specialized commercial and clinical services for injectables and parenterals include primary and secondary labeling of vials, IV bags, pre-filled syringes, and IV bottles in ambient, cold and ultra-cold environments; custom label generation; kitting; serialization and aggregation; and storage and distribution. Some of Sharp’s sterile packaging capabilities for injectable drug products include: Vial Labeling and Packaging: Sharp has decades of packaging experience and offers pharmaceutical packaging and labeling services for vials. Its contract packaging services include an automated visual inspection of labeling, tray and carton packing, cartoning of single and multipacks, tamper-evident solutions, cold-chain storage (2-8°C), and ultra-low temperature freezer banks (-20°C/-70°C). In addition to these services, Sharp provides package design; kitting; and segregated suites to handle highly potent APIs (HPAPI), cytotoxins, hormones; serialization and aggregation; and specialty distribution. Autoinjector and Pen Assembly, Labeling, and Packaging: Sharp excels in managing the complexities related to autoinjector or pen device labeling and packaging from its US and EU facilities. Moreover, its YpsoMate autoinjector device delivers a high level of technical accuracy required for the assembly of prefilled syringes into YpsoMate autoinjectors. Sharp’s experts also offer clinical trial packaging services and specialize in managing the challenges related to clinical trial logistics and packaging of biological formulations. Pre-Filled Syringe Assembly, Labeling, and Packaging: Sharp is a leader in the assembly, labeling, and packaging of pre-filled syringes and safety devices. It provides customized commercial and clinical pharma packaging services for both small and large-volume batch sizes for injectables. Small Scale Sterile Fill-Finish: Sharp partners with Berkshire Sterile Manufacturing (BSM) and offers high-quality, manufacturing, packaging, and distribution solutions for flexible fillers, BSM fills vials, cartridges, syringes, and lyophilization. Gene Therapy Clinical and Commercial Packaging: Sharp has over 70 years of experience in packaging complex pharmaceuticals such as low-volume, high-value gene therapies. Sharp is also engineered to provide demand-led supply commercial and clinical services including batch sizes as small as 1 vial, or packaging, labeling, and distribution in cold, ultra-cold, or cryogenic conditions. Sharp also has dedicated facilities in Bethlehem, PA, US, Heerenveen, and the Netherlands for handling gene therapies. These facilities are equipped with HEPA air handling systems; controlled temperature; humidity and dew point; full-sized -80°C freezer banks in dedicated production suites; constant monitoring of time-out-of-refrigeration, and specific freeze-thaw cycles. These facilities help in providing clinical trial packaging services and clinical secondary packaging solutions along with commercial packaging of sterile formulations. What range of pharmaceutical packaging solutions does Sharp offer for solid and liquid drug products? With a history spanning more than 70 years, Sharp is a pioneer in providing pharmaceutical packaging services that include primary and secondary packaging of solid, liquid, and semi-solid drug products for clinical and commercial scales from its state-of-the-art facilities. Sharp offers innovative and economical clinical packaging services for investigational medicinal products (IMP). It also supports the packaging of various dosage forms including bottling of solid formulations, and thermo and cold forming blister packaging for oral solids. Sharp also supports the packaging of powder and OSDs in sachets and pouches, oral and transdermal films in strips, and injectables in vials, syringes, and cartridges. Moreover, it is also involved in the packaging of semi-solids such as cream and ointment in tubes. Some of Sharp’s pharmaceutical packaging solutions for solid and liquid drug products are mentioned below: Bottle Packaging for Solids and Semi-solids: Sharp provides pharma packaging contract services for bottle packaging that include component sourcing, carton printing and in-line cartoning or bundling, comprehensive onsite engineering and validation support, serialization and aggregation, and strict quality control for packaged drugs. Sharp also offers high-quality nitrogen flush bottles and bottle packaging for moisture and oxygen-sensitive drugs. Blister Packaging for Oral Solids: Sharp provides various blister packaging solutions including thermoform and cold form blisters, patient packs, hospital unit dose packs, wallet cards, child-resistant lidding, sustainable foil and blister materials, and multiple products per blister. Apart from this, Sharp’s contract blister packaging services also involve multi-color foil printing, in-house tooling design and fabrication, polymer laminates (Aclar, PVC/PVDC, etc.) heat-seal coating resins, and automated visual inspection. Pouches and Sachets for Solids and Transdermal Patches (Primary and Secondary Packaging Services): Sharp has expertise in pouch and sachet packaging filled with solid dose, powder, thin film, and transdermal patch drug products. Sharp’s solid dose packaging solutions offer considerable pouch and sachet packaging backed by quality operations and project management knowledge. Sharp is home to a sizable assemblage of form, fill, and seal technologies. Based on decades of practical expertise, Sharp uses a wide range of innovative film structure materials, such as coated papers, high-barrier foils, and polymer laminates, and offers pharma packaging contract services. It also can support the production of multiple dosage forms for pharmaceutical products. Oral Thin Film and Transdermal Patches: Sharp provides primary and secondary packaging services for oral thin films and transdermal patches. Sharp specializes in die-cutting and pouching sublingual and oral dissolvable films, and transdermal drug delivery systems, and offers specialized pharmaceutical packaging services through quality procedures. It utilizes the most up-to-date solid dose packaging solutions and processes to safely package and safeguard specialty drug products. Sharp’s oral thin film and transdermal patch capabilities include highly accurate dosing by die-cutting laminated products to any size and shape; in-line printing of drug info, bar codes, lot number, expiration date, serialization with optical character verification (OCV); etc. Therefore, Sharp is a pharmaceutical contract packaging organization that offers clinical services, cold chain packaging, clinical packaging and labeling, and commercial packaging. Its pharmaceutical contract packaging service also encompasses primary and secondary clinical and commercial packaging. 

    Impressions: 196

    https://www.pharmacompass.com/pharma-blog/contract-packaging-primary-and-secondary-packaging-services-offered-by-sharp

    #LearnMore by PharmaCompass
    04 Mar 2024